Literature DB >> 14583638

Combination effect of ciprofloxacin and gentamicin against clinical isolates of Salmonella enterica serovar typhi with reduced susceptibility to ciprofloxacin.

Shyamapada Mandal1, Manisha Deb Mandal, Nishith Kumar Pal.   

Abstract

The present study evaluated the in vitro efficacy of ciprofloxacin (CPFX) in combination with gentamicin (GM) using agar dilution checkerboard method against six blood culture isolates of Salmonella enterica serovar Typhi with CPFX minimum inhibitory concentration (MIC) values of 0.75 - 1.25 microg/ml and GM MIC values of 0.75 - 2 microg/ml. When used in combination, the fractional inhibitory concentration (FIC) values of CPFX and GM for the isolates ranged from 0.008 - 0.032 microg/ml and 0.1 - 0.2 microg/ml, respectively. The range of the FIC index from 0.121 - 0.216 indicated the synergistic effect between CPFX and GM for all the isolates. The time-kill method, which showed a 2.64 log(10) decrease in CFU/ml between the combination and its more active compound, also established synergism between CPFX and GM against one isolate employed in the method. These results may be helpful in making clinical decisions in the treatment of enteric fever due to the infection of multidrug resistant S. enterica serovar Typhi.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583638

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  2 in total

Review 1.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

2.  Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.

Authors:  Nadine Lemaître; Isabelle Ricard; Elizabeth Pradel; Benoît Foligné; René Courcol; Michel Simonet; Florent Sebbane
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.